A new report from No Patient Left Behind argues that drug value assessments used outside the U.S. in markets such as Canada and Germany undervalue innovative medicines, claiming the process can shortchange societal benefits by as much as 90%. The group says this misleads U.S. policymakers and distorts debate over whether the U.S. overpays for drugs. The report points to quality-adjusted life year assumptions and “willingness-to-pay” thresholds it describes as outdated, and it criticizes HTAs for not capturing broader benefits to families and society—such as quicker return to work and reduced disability costs. It also says decision models may underweight practical factors like administration burden and travel costs. The release aligns with prior arguments from European CEOs at Sanofi and Novartis about the need to better reflect innovation-driven benefits in European HTA outcomes.